Access cutting-edge prodromal parkinson's disease treatment through this phase 2 clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this New Haven location
Preparing your pre-screening questions…
Access prodromal parkinson's disease specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related prodromal parkinson's disease treatment provided free
Check if you qualify for this prodromal parkinson's disease clinical trial in New Haven, CT
No-Cost Study Care
Local to New Haven
Convenient for CT residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is a single-center, longitudinal study and will be conducted at the Institute for Neurodegenerative (INDD) Site in New Haven, CT. This study aims to recruit participants from the ongoing Parkinson's Progression Markers Initiative AV-133 Prodromal Imaging sub study \[PPMI 015\] to obtain a second comparison imaging scan. In addition to being imaged with the standard Positron Emission Tomography (PET) camera after the \[18F\]AV133 injection in the PPMI 015 sub study, participants agreeing to a second scan will be imaged with the NeuroEXPLORER (NX) PET camera per this protocol. This study will enroll approximately 25 participants at the INDD site. The dual PET scans will be completed at baseline, 1-and 2- years follow up. Participants may be asked to undergo further longitudinal scans based on the acquired study data. All participants will have longitudinal clinical, biomarker, and genetic data for correlation analyses to imaging data from the PPMI Clinical study.
Sponsor: Michael J. Fox Foundation for Parkinson's Research
Yes, this clinical trial (NCT07809438) has an active research site in New Haven, CT that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for prodromal parkinson's disease treatment options in New Haven, CT, this clinical trial (NCT07809438) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced prodromal parkinson's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all prodromal parkinson's disease clinical trials near you to find additional studies recruiting in your area.
See all parkinsons disease clinical trials recruiting in New Haven — not just this study.
Browse Parkinsons Disease Trials in New Haven →